Kyowa Kirin pharma growth lacklustre despite strong Nesp sales
This article was originally published in Scrip
Executive Summary
Despite good growth for mainstay product Nesp (darbepoetin alfa; licensed from Amgen), net pharmaceutical sales at Kyowa Hakko Kirin rose by just 1% to ¥210.4 billion ($2.56 billion) in calendar 2010, held back mainly by last April's general reimbursement price cut in Japan.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Merck & Co progresses cardiovascular strategy; Novo purchase builds heart failure presence; CRL setbacks for Regeneron; ITF faces challenging Duchenne field; and AbbVie needs to freshen up.